NF-kB p65(RELA) (NM_021975) Human Recombinant Protein

CAT#: TP320780

Recombinant protein of human v-rel reticuloendotheliosis viral oncogene homolog A (avian) (RELA), transcript variant 1

Product images

• 

  Western blot analysis of the recombinant NFkBp65 preparation (OriGene TP320780) to check the specificity of two anti-NFkBp65 antibodies: A and C20X. NFkBp65 (25, 50, and 100 ng) was resolved on a NuPAGE 4 - 12% PAGE in MOPs buffer and subjected to Western blot. Figure cited from PLoS ONE, PMID: 25853889

• 

  EMSA examines NFkBp65 DNA binding activity. HIV-1 LTR DNA probe was incubated with 100 ng of purified NFkBp65 (OriGene TP320780), and the NFkBp65-DNA complexes were resolved on a 6% non-denaturing polyacrylamide/bisacrylamide gel. NFkBp65-DNA complexes were super-shifted by the addition of anti-NFkBp65 antibody. Anti-NFkBp50 antibody and anti-Myc IgG served as controls. The black arrows indicate the position of the NFkBp65-DNA complex; the grey arrow indicates free HIV-1 LTR DNA probe. The white arrows show the position of the complexes in the presence of the antibody. Figure cited from PLoS ONE, PMID: 25853889

• 

Specifications

Product Data

• Description: Recombinant protein of human v-rel reticuloendotheliosis viral oncogene homolog A (avian) (RELA), transcript variant 1
• Species: Human
• Expression Host: HEK293T
• Expression cDNA Clone or AA Sequence: Recombinant protein was produced with TrueORF clone, RC220780. Click on the TrueORF clone link to view cDNA and protein sequences.
• Tag: C-MYC/DDK
• Predicted MW: 60 kDa
• Concentration: >50 ug/mL as determined by microplate BCA method
• Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining
• Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol. Store at –80C. Avoid repeated freeze-thaw cycles. Stable for 3 months from receipt of products under proper storage and handling conditions.
• Bioactivity: RELA Activity Verified in a DNA-binding Assay: RELA activity was measured in a colorimetric DNA-binding assay. Double-stranded oligonucleotide containing the RELA consensus DNA-binding sequence was incubated with dilutions of the purified RELA protein. RELA bound to the oligo was captured onto the surface of a microtiter plate and after washing, bound RELA was detected with an anti-RELA primary antibody followed by an HRP-labeled secondary antibody. After initial color development, the reaction was quenched and the color intensity was measured at 450nm.
  ELISA binding assay (PMID: 25584020)
  WB positive control (PMID: 25853889)
  EMSA assay (PMID: 25853889)
  Binding assay (PMID: 26561547)
  Pull-down assay (PMID: 26984196)
• Preparation: Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps.

Reference Data

• RefSeq: NP_068810
• Locus ID: 5970
• Refseq Size: 1760
• Cytogenetics: 11q13.1
• Refseq ORF: 1653
• Synonyms: NFKB3; p65
• Summary: NF-kappa-B is a ubiquitous transcription factor involved in several biological processes. It is held in the cytoplasm in an inactive state by specific inhibitors. Upon degradation of the inhibitor, NF-kappa-B moves to the nucleus and activates transcription of specific genes. NF-kappa-B is composed of NFKB1 or NFKB2 bound to either REL, RELA, or RELB. The most abundant form of NF-kappa-B is NFKB1 complexed with the product of this gene, RELA. Four transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2011]
• Protein Families: Druggable Genome, Transcription Factors
• Protein Pathways: MAPK signaling pathway, Chemokine signaling pathway, Apoptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, T cell receptor signaling pathway, B cell receptor signaling pathway, Neurotrophin signaling pathway, Adipocytokine signaling pathway, Epithelial cell signaling in Helicobacter pylori infection, Pathways in cancer, Pancreatic cancer, Prostate cancer, Chronic myeloid leukemia, Acute myeloid leukemia, Small cell lung cancer